Axiomer® platform applicability and potential in therapeutically relevant models for targeted RNA editing presented at TIDES EU 2018 by Antti Aalto - ProQR Therapeutics
… the potential of new RNA editing technologies leveraging ADAR endogenous machinery This presentation reviews Axiomer … specific RNA for A-to-I editing by recruiting endogenous Adenosine Deaminase Acting on RNA (ADAR). The therapeutic possibilities of this editing …
… a new class of medicines. What is RNA and how can we use ADAR, the body's own RNA editing machinery to treat disease? … protect against unnecessary immune reactions. What is ADAR What is ADAR There are different ways in which RNA is …
ProQR invented an entirely new way to treat genetic diseases. Axiomer enables RNA base editing by recruiting ADAR so your own body can treat disease. Learn more here.
… Successful Defense of a Key Axiomer® Patent Protecting ADAR-mediated RNA Editing LEIDEN, Netherlands & CAMBRIDGE, … which is related to targeted RNA editing using endogenous ADARs and is part of ProQR’s intellectual property estate …
… ProQR Appoints Peter A. Beal, PhD, as Chief ADAR Scientist LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. … of ProQR and a valued member of ProQR’s Scientific Advisory Board, where he has played an important role in shaping the Company’s ADAR-based RNA editing platform. Dr. Beal’s decades of …
… and Director of the NIH-funded UC Davis Chemical Biology Graduate Program. For over 25 years, work in the Beal laboratory has advanced understanding of the structures and mechanism of action for the ADAR enzymes responsible for adenosine to inosine RNA editing …
